Type 1 Diabetes Mellitus
Conditions
Keywords
T1D, Omnipod
Brief summary
To assess the safety and performance of the Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4 Share® AP System and personalized model predictive control algorithm in adults with type 1 diabetes consuming high fat meals and undertaking moderate intensity exercise.
Detailed description
The two-part study schedule consists of a 7±1 day outpatient, open-loop phase, followed by one 54-hour, hybrid closed-loop phases conducted in a supervised CRC or hotel/rental house setting.
Interventions
DEVICEInsulet AP (artificial pancreas) System
Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4 Share® AP System and personalized model predictive control algorithm.
Sponsors
Insulet Corporation
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE
Intervention model description
The two-part study schedule consists of a 7±1 day outpatient, open-loop phase, followed by one 54-hour (Option A - Meal Performance and/or Option B - Exercise), hybrid closed-loop phases conducted in a supervised CRC or hotel/rental house setting. Subjects may participate in hybrid closed-loop session Option A and/or Option B.
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Age at time of consent 18.0 to 65.0 years 2. Diagnosed with type 1 diabetes for at least one year. Diagnosis is based on investigator's clinical judgment. 3. Total daily dose (TDD) of insulin ≥0.3 units/kg/day and A1C \>6% at screening 4. Currently using an insulin pump with U-100 rapid-acting insulin analogs and on pump therapy for at least 6 months prior to study start 5. Willing to use the study CGM device for the duration of the study 6. Willing to use the Omnipod® Insulin Management System during the study 7. Willing to perform all fingerstick BG testing with the study-approved glucose meter at the frequency specified in the study protocol 8. Willing to abide by meal recommendations for breakfast, lunch and dinner during the study 9. Willing to participate in moderate intensity exercise for up to 45 minutes if taking part in Option B 10. Willing to refrain from use of acetaminophen and supplemental vitamin C (\>2000 mg/daily) for the entire duration of participation in the study 11. Willing and able to sign the Informed Consent Form (ICF)
Exclusion criteria
1. A1C \>10% at the screening visit 2. One or more episodes of severe hypoglycemia requiring emergency room (ER) visit or hospitalization within the past 6 months 3. Hypoglycemic unawareness as determined by a score of ≥4 R responses on the Clarke Questionnaire 4. One or more episodes of diabetic ketoacidosis requiring ER visit or hospitalization within the past 6 months 5. Used non-insulin anti-diabetic medication within last 30 days 6. Pregnant or lactating, or is a woman of childbearing potential and not on acceptable form of birth control (acceptable includes abstinence, condoms, oral/injectable contraceptives, IUD or implant) 7. Dermatological conditions at the proposed sensor wear sites that in the investigator's opinion could preclude ability to wear the Pod and/or the Dexcom sensor 8. Current or known history of cardiovascular disease, arrhythmia, myocardial infarction (MI) or stroke. An electrocardiogram (ECG) must be obtained within 6 months. 9. Currently undergoing systemic treatment with steroids or immunosuppressive medication 10. Current illness that would interfere with participation in the study 11. Currently participating in another clinical study using an investigational drug or device 12. Recent (within the preceding 30 days) participation in a clinical study using an investigational drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of time in hypoglycemic range (defined as < 70 mg/dL) | 54 hours |
| Percentage of time in hyperglycemic range(defined as ≥ 250 mg/dL) | 54 hours |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of time < 60 mg/dL | 54 hours | — |
| Percentage of time > 180 mg/dL | 54 hours | — |
| Percentage of time ≥ 300 mg/dL | 54 hours | — |
| Percentage of time between 70-180 mg/dL | 54 hours | — |
| Percentage of time between 70-140 mg/dL | 54 hours | — |
| Standard deviation | 54 hours | — |
| Mean glucose | 54 hours | — |
| Meal challenge-12 hour PPG dinner | 54 hours | The post-prandial glucose response including time to peak glucose, peak glucose concentration, and peak glucose excursion and the 12-hour post-prandial period following dinner. |
| Meal challenge-4 hour PPG breakfast | 54 hours | The post-prandial glucose response including time to peak glucose, peak glucose concentration, and peak glucose excursion for the 4-hour post-prandial period following breakfast. |
| Meal challenge-4 hour PPG lunch | 54 hour | The post-prandial glucose response including time to peak glucose, peak glucose concentration, and peak glucose excursion for the 4-hour post-prandial period following lunch. |
| Exercise challenge-immediate and delayed glucose response | 54 hour | The immediate (2 hours) and delayed (24 hours) glucose response to moderate intensity exercise. |
| Effect of changing setpoints | 54 hour | Effect of changing setpoints to overall performance. |
| Coefficient of variation | 54 hours | — |
| Percentage of time < 50 mg/dL | 54 hours | — |
Countries
United States
Outcome results
None listed